School of Engineering
Pharmaceutical Chemistry Group
(GQF)
2021 SGR 00533
The GQF group research focuses on two main areas:
1) The Pharmaceutical Chemistry Unit (new drugs): pharmaceutical and cosmetics formulation, applied biology and API production within the areas of Biomedicine and Health Sciences.
2) The Continuous Chemical Processes Unit: application of new advanced manufacturing technologies in fine chemistry, to transform and optimise production systems from batch to continuous, making them more efficient, more stable, safer, faster and cleaner.
This range of services is offered through the use of the unit’s continuous reaction equipment: the Syrris ASIA reactor for small trials, and the TITAN for scale-up and production of small batches, in the order of a kilo of product. The Process Analytical Technologies (PAT) allow the continuous monitoring of the processes and guarantee the quality of their results.
In this environment, GQF carries out its R&D and technology transfer activities in the following areas:
- Tyrosine kinase inhibitors with application for cancer (lung, breast and pancreatic)
- Compounds with activity against chemokine-like receptors (CXCR4 inhibitors)
- Compounds with activity against myotonic dystrophy
- Screening and selection of chemical reactions, with the help of microwave reactors
- Laboratory tests for the development of new processes or for the improvement of existing ones
- Process optimisation by design of experiments (DoE)
- Scale-up of new or existing processes
- Small batch production
COORDINATOR:
Roger Estrada Tejedor, PhD
Head of GQF Group - Head of Molecular Design Lab. - Associate Professor
+34932672000
SEE MORE
MEMBERS:
Eduard Serra Hosta, PhD
Head of Thermal Analysis Laboratory - Assistant Professor
+34932672000
SEE MORE
Jordi Teixidó Closa, PhD
Vice-Rector for Research and Innovation URL - Professor
+34932672000
SEE MORE
EXTERNAL COLABORATORS
Santiago Ramon y Cajal, PhD
Hospital Vall d'Hebron
Gaël Roué, PhD
Institut Josep Carreras
LINKED NEWS
Research
New MNK Inhibitor Against Resistance to Cancer Therapies
13/11/2023
Researchers from IQS and VHIR are working together on the MnkImmunOnco project with the aim of bringing a new MNK inhibitor to the clinical phases of development to improve the response in cancer therapies.
READ FULL NEW
Doctoral thesis
New Synthetic Methodologies for Tyrosine Kinase Inhibitors in Pancreatic Cancer
05/07/2023
Dr Claudi de Rocafiguera recently defended his doctoral thesis at IQS, in which he established an improved synthesis pathway of pyrido[2,3-d]pyrimidin-7(8H)-ones, identifying a multitarget TKI inhibitor candidate against pancreatic ductal adenocarcinoma.
READ FULL NEW
Research
New Tyrosine Kinase Inhibitors Against Lymphoma
09/05/2023
Researchers from the IQS Pharmaceutical Chemistry Group and the Josep Carreras Leukaemia Research Institute are collaborating on the DisX4lymph project to look for new agents for the treatment of aggressive B-cell lymphoma.
READ FULL NEW
Doctoral thesis
TKI inhibitors for lypmhoma therapies
31/03/2023
Dr Victor Masip recently defended his doctoral thesis at IQS, in which he designed, synthesized, and characterized potential new inhibitors of the ZAP-70 protein for peripheral T lymphoma therapies.
READ FULL NEW
Doctoral thesis
Exploring Molecular Diversity, Searching for New Active Molecules
31/01/2023
In her doctoral thesis, Dr Leticia Manén has implemented a chemoinformatics methodology based on the selection of potentially active molecules, going far beyond the processes of hit-to-lead optimization and the claimed Markush space.
READ FULL NEW
Doctoral thesis
New In Vitro Predictive Models for Pancreatic Cancer
09/01/2023
Dr Nausika Betriu recently defended her doctoral thesis at IQS, in which she studied various aspects related to the progression of pancreatic cancer using physiological models based on three-dimensional cultures.
READ FULL NEW
Research
Fighting Against Emerging Drugs
16/03/2022
IQS participates in the European project NEXTGenPS, with the aim of detecting addictive and potentially hallucinogenic substances and facilitating the implementation of control measures for them in the European Union.
READ FULL NEW
Research
New Synthesis Challenges. BISiboNds Project
21/01/2022
Researchers from IQS and IQAC are working together on the development of new synthetic methodologies where they explore the combined use of catalytic systems with the great versatility of chemical elements such as Boron, Iodine and Silicon.
READ FULL NEW
7 Questions for...
Beatrice Ravasio
05/03/2021
Beatrice is a doctoral Student in Industrial Engineering with the Department of Chemical Engineering and Materials Science at the IQS School of Engineering.
READ FULL NEW
News
Continuous Chemical Processes Unit. Services for industry
05/03/2021
The offer of R&D&i services that IQS Tech Transfer provides companies has been expanded since 2020 with the launch of the Continuous Chemical Processes Unit, installed in the CTPTI at IQS, which is aimed at improving fine chemistry processes to make them safer, faster, and cleaner.
READ FULL NEW
News
Continuous Chemical Processes Unit. Auxiliary analytical services.
05/03/2021
With Process Analytical Technology (PAT), it is possible to monitor the reactions that take place in the Flow Chem Unit reactors. Moreover, any substance or mixture can be characterized with the equipment in the Thermal Analysis Laboratory (DSC and TGA).
READ FULL NEW
News
Continuous Chemical Processes Unit. Facilities and Equipment
04/03/2021
The facilities and equipment at the CTPTI Continuous Chemical Processes Unit make it possible to apply new advanced manufacturing technologies in fine chemicals, which opens up the possibility of comprehensively developing safer, faster, and cleaner chemical processes.
READ FULL NEW
Editorial
Continuous Chemical Processes Unit
04/03/2021
Through the publication and dissemination of this special issue dedicated to the Continuous Chemical Processes Unit, we would like to present the facility, the equipment and instruments that comprise it, the various services that we can offer to industry, and the excellent personnel without whom the project would not be a reality.
READ FULL NEW
LATEST PROJECTS
DisX4lymph (Interrupción de la interacción estroma-tumor en linfoma B utilizando inhibidores CXCR4 y degradadores IRAK4)
Diseño y síntesis de inhibidores alostéricos de CXCR4 y degradadores de IRAK4 como potencial tratamiento de linfoma de células B.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
NanoPan-3D (Desarrollo de nuevos nano-vehículos para superar la resistencia a fármacos del adenocarcinoma pancreático y su validación mediante modelos celulares 3D mixtos)
Nanoterapia para superar la resistencia a fármacos del adenocarcinoma pancreático.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
PreClinIQS080 (Estudio Preclínico Inicial de IQS080, un candidato a fármaco contra el cáncer de páncreas)
Estudio Preclínico de un potente inhibidor multidiana in vitro dirigido a tirosina quinasas intracelulares implicadas en el cáncer de páncreas
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
